Hvivo Plc (CRO)
XSTU
Closed
Oct 9, 2026
Day's Range
0.070052 wk Range
0.0280Overview - CRO - Hvivo Plc
Key Statistics
Valuation
Enterprise Value
45.58M
Price / Sales (TTM)
‪0.96‬
EV / EBITDA
‪17.47‬
Profitability
Operating Margin
‪-7.39%‬
Return on Assets
‪-8.34%‬
Return on Equity
‪-15.70%‬
Ownership
Shares Outstanding
687.01M
Price stats
50-Day Avg
‪0.0548‬
200-Day Avg
‪0.0926‬
Dividends
Frequency
Annual
Market Cap - CRO - Hvivo Plc
Peers - CRO - Hvivo Plc
Peer Comparison
Compared with companies in Biotechnology listed on XSTU.
- CROXSTUHvivo Plc45.09MMarket Cap+5.71%52-week change—P/E (Trailing)—Profit Margin
- 6IBXSTUInnovent Biologics Inc.14.71BMarket Cap+6.26%52-week change—P/E (Trailing)‪86.53%‬Profit Margin
- 4KBXSTUKrystal Biotech, Inc.8.99BMarket Cap+52.99%52-week change43.02P/E (Trailing)‪54.81%‬Profit Margin
- 19XXSTUAxsome Therapeutics Inc.7.98BMarket Cap+41.36%52-week change-46.29P/E (Trailing)‪92.56%‬Profit Margin
- 2X10XSTUAbivax SA Sponsored ADR7.19BMarket Cap+12.50%52-week change-16.56P/E (Trailing)‪0.00%‬Profit Margin
- 30JXSTUIDEAYA Biosciences Inc.3.10BMarket Cap+29.17%52-week change-25.15P/E (Trailing)‪-74.75%‬Profit Margin
- BSFAXSTUAni Pharmaceuticals, Inc.1.49BMarket Cap-19.23%52-week change16.21P/E (Trailing)‪11.07%‬Profit Margin
Profile Summary - CRO - Hvivo Plc
About
Hvivo Plc is a pioneering entity in the clinical research and pharmaceutical development landscape. Its core function is to conduct human challenge studies, which involve intentionally exposing healthy volunteers to a particular pathogen to study infectious and respiratory diseases in a controlled environment. This…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
